Background: In addition to clinical efficacy, patient-defined benefit assessment has become an important outcome parameter. Thus far, no such instrument has been developed for vitiligo. Objectives: Development and validation of a patient-defined benefit questionnaire in the therapy of vitiligo. Methods: Open questioning of 50 vitiligo patients generated 110 benefit items, which were converted into a 26-item questionnaire by a panel of dermatologists, psychologists and patients. This was used to record patient-defined needs prior to therapy and to evaluate patient benefit attained after therapy. A ‘patient benefit index’ (PBI) was formed on the basis of both. Validation was based on data of n = 1,023 vitiligo patients. Results: The questionnaires were feasible in clinical practice, Cronbach’s α (patient need questionnaire) was 0.94. The PBI showed convergent and discriminant validity with respect to quality of life and patient satisfaction. Conclusion: The PBI for vitiligo is a valid instrument, which is highly accepted in practice for recording patient-reported benefit.

Hahn SK, Nordlund JJ: Vitiligo. Oxford, Blackwell Sciences, 2000.
Arrunategui A, Arroyo C, Garcia L, Covelli L, Escobar C, Carrascal C, Falabella R: Melanocyte reservoir in vitiligo. Int J Dermatol 1994;33:484–487.
Salzer BA, Schallreuter KU: Investigation of the personality structure in patients with vitiligo and a possible association with impaired catecholamine metabolism. Dermatology 1995;190:109–115.
Schallreuter KU: Verdammte weisse Fle- cken. Bradford, University of Bradford, 1995.
Mechri A, Amri M, Douarika AA, Ali Hichem BH, Zouari B, Zili J: Psychiatric morbidity and quality of life in vitiligo: a case controlled study. Tunis Med 2006;84:632–635.
Ongenae K, Dierckxsens L, Brochez L, van Geel N, Naeyaert JM: Quality of life and stigmatisation profile in a cohort of vitiligo patients and effect of the use of camouflage. Dermatology 2005;210:279–285.
Ongenae K, Van Geel N, De Schepper S, Naeyaert JM: Effect of vitiligo on self-reported health-related quality of life. Br J Dermatol 2005;152:1165–1172.
Belhadjali H, Amri M, Mechri A, Doarika A, Khorchani H, Youssef M, Gaha L, Zili J: Vitiligo and quality of life: a case control study. Ann Dermatol Vénéréol 2007;134:233–236.
Borimnejad L, Parsa Yekta Z, Nikbakht-Nasrabadi A, Firooz A: Quality of life with vitiligo: comparison of male and female muslim patients in Iran. Gend Med 2006;3: 124–130.
Fitzpatrick T, Eisen A, Wolff K, Freedberg I, Austen K (eds): Dermatology in General Medicine, ed 4, revised. New York, McGraw-Hill, 1993.
Van Geel N, Ongenae K, Haeghen YV, Vervaet C, Naeyert JM: Subjective and objective evaluation of noncultured epidermal cellular grafting for repigmenting vitiligi. Dermatology 2006;213:23–29.
Rychlik R, Rusche H, Augustin M: Systematik der Nutzenbewertung von Arzneimitteln. Gesundh Ökon Qual Manag 2004;9:245–252.
Zentner A, Velasco-Garrido M, Busse R: Methods for the comparative evaluation of pharmaceuticals. GMS Health Technol Assess 2005, vol 1, doc 09. (accessed May 29, 2007).
Bundesministerium für Gesundheit: Gesetz zur Stärkung des Wettbewerbs in der gesetzlichen Krankenversicherung vom 26.03.2007. Bundesanzeiger 2007;66:3613.
Fünftes Buch Sozialgesetzbuch (SGB V), § 35b Abs 1.
Bastian H, Bender R, Ernst AS, Kaiser T, Kirchner H, Kolominsky-Rabas P, Lange S, Sawicky PT, Weber M: Methoden. Version 2.0 vom 19.12.2006. Köln, Institut für Qua- lität und Wirtschaftlichkeit im Gesundheitswesen, 2007.
Gemeinsamer Bundesausschuss: Verfahrensordnung vom 20.09.2005. Bundesanzeiger 2005;242:16998.
Zschocke I, Hammelmann U, Augustin M: Therapeutischer Nutzen in der dermatologischen Behandlung. Hautarzt 2005;56:839–846.
Bowling A: Measuring disease: a review of disease-specific quality of life measurement scales. Buckingham, Open University Press, 1995.
Brock D: Quality of life measures in health care and medical ethics; in Spilker B (ed): Quality of Life and Pharmacoeconomics in Clinical Trials, ed 2, revised. Philadelphia, Lippincott-Raven, 1996, pp 487–510.
Guyatt GH, Walter S, Norman G: Measuring change over time: assessing the usefulness of evaluative instruments. J Chron Dis 1987; 40:171–178.
Lienert G: Testaufbau und Testanalyse, ed 5. Weinheim, Beltz, 1994.
Smith GT (ed): Measuring Health: A Practical Approach. Chichester, Wiley, 1988.
Clark MS, Caudrey DJ: Evaluation of rehabilitation services: the use of goal attainment scaling. Int Rehabil Med 1982;5:41–45.
Ottenbacher KJ, Cusick A: Goal attainment scaling as a method of clinical service evaluation. Am J Occup Ther 1990;44:519–525.
Fisher K, Hardie RJ: Goal attainment scaling in evaluating a multidisciplinary pain management programme. Clin Rehabil 2002;16: 871–877.
Rushton PW, Miller WC: Goal attainment scaling in the rehabilitation of patients with lower-extremity amputations: a pilot study. Arch Phys Med Rehabil 2002;83:771–775.
Rockwood K, Howlett S, Stadnyk K, Carver D, Powell C, Stolee P: Responsiveness of goal attainment scaling in randomized controlled trial of comprehensive geriatric assessment. J Clin Epidemiol 2003;56:736–743.
Steinbook RM, Jacobson AF, Mosher JC, Davies DL: The goal attainment scale: an instructional guide for the delivery of social reinforcement. Arch Gen Psychiatry 1977; 34:923–926.
Steffanowski A, Lichtenberg S, Schmidt J, Huber C, Wittmann WW, Nübling R: Ergebnisqualität psychosomatischer Rehabilitation: Zielerreichungsskalierung auf der Basis einer strukturierten Therapiezielliste. Rehabilitation 2004;43:219–232.
Zwingmann C: Zielorientierte Ergebnismessung (ZOE) mit dem IRES-Patientenfragebogen: Eine kritische Zwischenbilanz. Rehabilitation 2003;42:226–235.
Augustin M, Amon U, Braathen L, Bullinger M, Gieler U, Klein GF, Schultz-Amling W: Erfassung von Lebensqualität in der Dermatologie (Leitlinie). JDDG 2004;9:802–806.
The EuroQol group: EuroQol – a new facility for the measurement of health related quality of life. Health Policy 1990;16:199–208.
Finlay AY, Khan GK: Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210–216.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.